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Multimodal Magnetic Resonance 
and Near-Infrared-Fluorescent 
Imaging of Intraperitoneal Ovarian 
Cancer Using a Dual-Mode-Dual-
Gadolinium Liposomal Contrast 
Agent
M. K. Ravoori1, S. Singh1, R. Bhavane2, A. K. Sood3, B. Anvari4, J. Bankson5, A. Annapragada2 
& V. Kundra1,6
The degree of tumor removal at surgery is a major factor in predicting outcome for ovarian cancer. A 
single multimodality agent that can be used with magnetic resonance (MR) for staging and pre-surgical 
planning, and with optical imaging to aid surgical removal of tumors, would present a new paradigm for 
ovarian cancer. We assessed whether a dual-mode, dual-Gadolinium (DM-Dual-Gd-ICG) contrast agent 
can be used to visualize ovarian tumors in the peritoneal cavity by multimodal MR and near infra-red 
imaging (NIR). Intraperitoneal ovarian tumors (Hey-A8 or OVCAR3) in mice enhanced on MR two days 
after intravenous DM-Dual Gd-ICG injection compared to controls (SNR, CNR, p < 0.05, n = 6). As seen 
on open abdomen and excised tumors views and confirmed by optical radiant efficiency measurement, 
Hey-A8 or OVCAR3 tumors from animals injected with DM-Dual Gd-ICG had increased fluorescence 
(p < 0.05, n = 6). This suggests clinical potential to localize ovarian tumors by MR for staging and 
surgical planning, and, by NIR at surgery for resection.
Ovarian cancer is the most lethal gynecologic malignancy1. Nearly 75% of patients are first diagnosed with tumor 
within the peritoneal cavity (intraperitoneal disease), portending poor survival2. Surgery is the frontline inter-
vention. Locating and characterizing tumor implants is critically important for staging and pre-surgical planning. 
Clinically, CT or MR + traditional extravascular-extracellular contrast is used for staging and pre-surgical plan-
ning, but are limited in sensitivity for tumor detection and in distinguishing benign from malignant disease3–6. 
Moreover, tumor enhancement is only temporary on the order of minutes, which is acceptable for rapid diag-
nostic tests but not if one also wants to mark tumors for surgical resection days later. Locating tumor implants 
and then removing them at the time of surgery is important for outcome. In fact, the degree of cytoreduction, i.e. 
tumor resection, at surgery is one of the most important factors predicting overall survival, with improved sur-
vival associated with complete resection of all visible cancer7,8. Practically, this commonly translates into remov-
ing all > 1–2 cm lesions visible by the naked eye9. Detecting even these in the large space of the peritoneum is 
challenging. A multimodality agent that can be used for MR for staging and pre-surgical planning and for optical 
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imaging to aid surgical removal of ovarian cancer would present a new paradigm in clinical imaging of ovarian 
cancer.
MR has greater soft-tissue contrast than CT and does not use ionizing radiation. Traditional 
extravascular-extracellular contrast agents enhance lesions for only a few minutes. The dual-Gd platform with 
both surface and encapsulated Gd has greater relaxivity than only surface Gd or only encapsulated Gd lipos-
omes, and has approximately 10,000 times greater relaxivity/particle than traditional extravascular-extracellular 
agents and has been shown to increase SNR, for example, for vascular imaging10. Because of its diameter 
(≈ 100–250 nm), it should extravasate via enhanced-permeability-and-retention-effect (EPR). This occurs 
in nearly all solid tumors but not normal tissues and is attributable to abnormal angiogenic vessels in tumors. 
Moreover, similar liposomes are retained in tumors for 2–3 days or longer11.
Among optical imaging techniques, NIR affords low background and greater depth of penetration than visible 
light12–14. This real-time technique has been proposed for use during surgery15,16. Among NIR agents, only ICG 
is clinically approved, primarily for eye angiography17. Free ICG has a short plasma half-life (~2–4 minutes)18,19. 
Encapsulation increases circulation time and delays maximal hepatic accumulation (> 1 hour)20. Encapsulation 
can also increase in vivo stability, and signal intensity21.
Clinically, imaging agents are needed that can detect and characterize peritoneal lesions as metastases. A high 
relaxivity nanoparticle with dual modality MR and NIR capability and long term retention in tumor may also find 
clinical utility for first pre-surgical planning and then lesion detection at surgery. The purpose of this work was to 
assess whether a dual mode, dual gadolinium liposomal contrast agent (DM-Dual-Gd-ICG, Fig. 1) can be used to 
visualize intraperitoneal ovarian tumors by multimodal MR and NIR imaging.
Results
Liposomes. Five batches of liposomes were prepared and characterized (Table 1). All of the batches exhib-
ited nearly equivalent mean diameter and polydispersity index. The cumulative size distributions of all batches 
showed that 100% of the particles were between 100 and 200 nm, most < 150 nm. Gd, P, and ICG levels in all 
batches were similar. Phosphorus levels indicated a total lipid concentration of ~100 mM, compared to the nom-
inal value of 150 mM estimated from the starting lipid amounts, suggesting ~33% loss of lipids during the extru-
sion process, consistent with previous experience.
ICG leak from the particles over time at 37 °C in plasma was undetectable (Fig. 2A); an initial ~20% leak of 
Gd-chelate was noted at 2 hours when this plateaued and no further leak was seen (Fig. 2B). T1 relaxation rates 
(R1) (Fig. 2C) and total radiant efficiency (Fig. 2D) of the two different batches used for animal experiments 
(batch-1 and batch-2) were similar. Thus, there was good batch to batch reproducibility.
Figure 1. (A) Schematic of a Dual-Gd ICG liposome. It consists of a bilayer of lipid molecules encapsulating 
an aqueous interior of Gd-chelate and ICG molecules. The encapsulated Gd-chelate and the surface lipid-Gd-
chelate provide contrast for MRI. The ICG is used in near-infrared imaging (NIR). The polyethylene glycol 
(PEG) conjugated to lipid increases the circulating time of the liposomes by avoiding reticuloendothelial cell 
system (RES) clearance.
DM-Dual-
Gd-ICG
Mean 
Diameter (nm)
Polydispersity 
Index
Cumulative Particle Size Distribution
Gd (mM) P (mM) Lipid (mM)
Estimated 
ICG (pM)% <200 nm % <150 nm % <100 nm
Batch-1 135 + /− 11 0.08 + /− 0.03 100 95 + /− 9 0 66.50 + /− 1.52 39.60 + /− 0.65 113.00 + /− 1.86 49
Batch-2 137 + /− 20 0.06 + /− 0.07 100 67 + /− 58 0 66.60 + /− 0.11 35.4 + /− 0.26 101.20 + /− 0.76 44
Batch-3 136 + /− 4 0.06 + /− 0.05 100 100 0 75.57 + /− 0.36 36.34 + /− 0.55 103.81 + /− 1.56 45
Batch-4 155 + /− 2 0.04 + /− 0.03 100 62 + /− 13 0 84.73 + /− 1.20 35.78 + /− 0.35 102.21 + /− 1.00 44
Batch-5 147 + /− 1 0.01 + /− 0.00 100 99 + /− 2 0 78.71 + /− 4.76 36.78 + /− 0.18 105.10 + /− 0.51 46
Table 1. DM-Dual-Gd-ICG Batch Characteristics. 
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MR and NIRF imaging. Intraperitoneal tumors were established using human ovarian cancer HeyA8 cells 
or OVCAR-3 cells. Two days after injection, HeyA8 tumors from mice injected with DM-Dual-Gd-ICG had 
greater enhancement compared to tumors from control mice as seen by in vivo MR (Fig. 3A). The mice were then 
sacrificed and immediately, optical NIR imaging followed, which again demonstrated increased signal in HeyA8 
tumors from mice injected with DM-Dual-Gd-ICG compared to tumors from control mice (Fig. 3B and C). 
Similar MR and NIR findings were noted with a second intraperitoneal tumor model, OVCAR-3 (Fig. 3D–F). 
Reticuloendothelial system (RES) uptake in the liver and spleen is expected with liposomal agents; and, via hepa-
tobilliary excretion, signal in the bowel (and with reflux, in the stomach) is expected and would move in time 
due to peristalsis in a live animal. Physiologically, the degree of excretion and peristalsis is expected to be variable 
between individual mice. To determine if leakage of encapsulated ICG or MR contrast agent from liposomes 
resulted in findings at the 48 hour time point, in vivo studies were performed using mice bearing intraperitoneal 
HeyA8 or OVCAR3 tumors. For robustness, non-encapsulated ICG or gadobenate dimeglumine was injected 
at the full dose expected to be delivered with DM-Dual-Gd-ICG liposomes, as if the liposomes leaked 100% of 
their payload. Immediately after injection, HeyA8 tumors from mice injected with gadobenate dimeglumine 
enhanced compared to the same animal tumors before injection as expected but not two days after injection 
(Fig. 3G). Likewise, two days after injection, no signal was seen in HeyA8 tumors by NIR imaging (3H and I). 
Similar MR and NIR findings were noted with the OVCAR3 model (Fig. 3J,K and L), thus, the signal seen at 
48 hours (Fig. 3A–F) was due to the liposome formulation. The MR signal-to-noise ratio and contrast-to-noise 
ratio were significantly greater in HeyA8 tumors from mice injected with DM-Dual-Gd-ICG than tumors from 
control mice (p < 0.001 SNR, p < 0.01 CNR, n = 6, Fig. 4A and C). Similar findings were noted with the second 
intraperitoneal tumor model, OVCAR-3 (p < 0.01 SNR, p < 0.001 CNR n = 5, Fig. 4B and D). Differences in 
the degree of signal are expected when using two different tumor models. In control studies, signal-to-noise 
and contrast-to-noise MR ratios were increased in HeyA8 tumors immediately after iv injection with gadobe-
nate dimeglumine (p < 0.001, n = 6, Fig. 4E and G) compared to before injection as expected, but not two days 
after injection; no difference in signal was seen two days after injection versus before injection. Similar findings 
were noted with the OVCAR3 model (p < 0.001, n = 6, Fig. 4F and H). Significantly, in both models, increased 
T1-weighted MR signal could be visualized in intraperitoneal tumors in mice two days after DM-Dual-Gd-ICG 
injection.
Ex vivo NIRF Imaging. Immediately after whole body optical NIR imaging, ex-vivo imaging of tum-
ors and organs was performed. HeyA8 tumors from mice injected with DM-Dual-Gd-ICG had greater sig-
nal compared to tumors from control mice (Fig. 5A) whereas mice injected with ICG had no increased signal 
(Fig. 5E). As expected with DM-Dual-Gd-ICG, signal was also seen in extracted organs such as the liver and 
spleen (Fig. 5B). In addition, hepatobilliary excreted material is expected in the intestines and, via reflux, in the 
stomach (Fig. 5B). Similar findings were noted with the OVCAR-3 model (Fig. 5C,D and F). Semi-quantitative 
Figure 2. In vitro leak study of liposomes in plasma at 37 °C for 48 hours. (A) ICG and (B) Gd-chelate in 
triplicate. T1 relaxation rate (R1) (C) and total radiant efficiency (D) of two batches of DM-Dual-Gd-ICG are 
similar. Dilutions of different batches of DM-Dual-Gd-ICG were measured by MR (C) or by NIRF (D) imaging.
www.nature.com/scientificreports/
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evaluation of fluorescence intensity in intraperitoneal HeyA8 tumors showed significantly greater signal in the 
DM-Dual-Gd-ICG group compared to the control group (p < 0.04, n = 6, Fig. 6A). No increased signal was seen 
in the ICG group (Fig. 6C). Similar findings were noted with a second intraperitoneal tumor model, OVCAR-3 
(p < 0.001, Fig. 6B and D). There was some variability in the degree of uptake of DM-Dual-Gd-ICG by the tum-
ors, as has been reported with other liposomal formulations previously. Differences in the degree of signal are 
expected when using two different tumor models. Significantly, in both models, increased NIR signal could be 
visualized in intraperitoneal tumors in mice two days after DM-Dual-Gd-ICG injection.
Discussion
This is the first demonstration of dual mode MR and NIR imaging of tumors using a single positive contrast 
nanoparticle in peritoneal human ovarian cancer models. The agent has long term residence in ovarian tumors, 
therefore, after a single injection, it enables MR imaging followed by optical NIR imaging. In addition to lesion 
detection and characterization, there is potential for MR imaging for pre-surgical planning followed by NIR 
imaging at the time of surgery for lesion detection and resection.
Dual mode imaging can be advantageous compared to single mode imaging. Strengths of MR include exqui-
site display of anatomy enabling an understanding of signal from a nanoparticle in context of anatomic surround-
ings, percutaneous imaging in vivo that is generally not depth limited, and resolution on the order of millimeters 
Figure 3. In vivo MR imaging and NIRF imaging shows that DM-Dual-Gd-ICG results in enhancement of 
HeyA8 tumors 2 days later. Representative axial 2D-FSPGR MR images of mice injected IV with DM-Dual-
Gd-ICG (top) or vehicle (bottom) (A). Representative coronal necropsy (B) and coronal open abdomen near 
infrared fluorescence images (C) of a nude mice. In vivo MR imaging and NIR imaging shows that DM-Dual-
Gd-ICG liposomes results in enhancement of OVCAR-3 tumors 2 days later. Representative axial 2D-FSPGR 
MR images of mice injected IV with DM-Dual-Gd-ICG (top) or vehicle (bottom) (D). Representative coronal 
necropsy (E) and coronal open abdomen near infrared fluorescence images (F) of a nude mice. Representative 
MR and NIR imaging show that free ICG or gadobenate dimeglumine do not result in increased signal in 
HeyA8 tumors 2 days after IV injection. Representative axial 2D-FSPGR MR images pre, immediate-post and 
2 days after IV injection of gadobenate dimeglumine (G). Representative coronal necropsy (H) and coronal 
open abdomen near infrared fluorescence images (I) of nude mice. Representative MR and NIR imaging show 
that free ICG or gadobenate dimeglumine do not result in increased signal in OVCAR3 tumors 2 days after IV 
injection. Representative axial 2D-FSPGR MR images pre, immediate-post and 2 days-post after IV injection 
of gadobenate dimeglumine (J). Representative coronal necropsy (K) and coronal open abdomen near infrared 
flouresence images (L) of a nude mice. Arrow, tumor; I, intestine; K, kidney; L, Liver.
www.nature.com/scientificreports/
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Figure 4. Quantitative assessment of signal-to-noise ratio of DM-DualGd-ICG uptake in intraperitoneal 
(A) HeyA8 tumors and (B) OVCAR3 tumors and contrast-to-noise ratio of DM-DualGd-ICG uptake in 
intraperitoneal (C) HeyA8 tumors and (D) OVCAR3 tumors 48 hours after injection using MRI. *P < 0.05; 
n = 6 Hey-A8, n = 5 OVCAR3. Quantitative assessment of signal-to-noise ratio pre, immediate-post and 2 days 
after IV gadobenate dimeglumine in (E) HeyA8 tumors and (F) OVCAR3 tumors and contrast-to-noise ratio 
pre, immediate-post and 2 days after IV gadobenate dimeglumine in (G) HeyA8 tumors and (H) OVCAR3 
tumors. *P < 0.05; n = 6 Hey-A8, n = 6 OVCAR3.
www.nature.com/scientificreports/
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clinically; however, MR machines are not used during abdominal surgery. Because signal detection can be lim-
ited in MR, amplification at the level of the nanoparticle, such as afforded by the Dual-Gd approach, is needed. 
Strengths of optical imaging include enabling dynamic imaging in the real time of surgery which should allow 
lesion detection and confirmation of resection, portable imaging systems that may be used in the operating room 
environment, fluorescence and white light imaging to enhance visualization of the lesion and surrounding elo-
quent anatomy, and spatial resolution at the < 100 nm scale22. NIR imaging enables better depth of penetration 
(1–2 cm) than visible light imaging, however, this still is inadequate for percutaneous imaging for tumor staging 
and treatment planning. The dual mode nanoparticle design includes external and internal Gd-chelates for MR 
imaging, ICG for NIR imaging, and PEGylation to avoid RES uptake. It enables EPR effect for tumor localization; 
increased duration of MR and optical signal in the tumor compared to standard extravascular-extracellular MR 
agents or high dose ICG alone; signal amplification; long residence time to enable pre-surgical planning and 
surgery, and, to potentially improve clinical workflow efficiency for MR by providing a long window between 
nanoparticle injection and MR imaging. We applied DM-Dual Gd-ICG to ovarian cancer models.
Ovarian cancer is most commonly diagnosed at an advanced stage with approximately three-quarters of 
patients presenting with peritoneal implants at the time of diagnosis2. Imaging of patients with advanced dis-
ease is usually performed using CT, MR, or PET/CT. Detection is limited by implant size as well as location 
and reports comparing percutaneous imaging modalities have had mixed findings regarding the superior-
ity of any one test4,5,23–28. Both PET and CT utilize ionizing radiation, whereas, MR does not making it poten-
tially safer. Mechanistically, both CT and MR intravenous contrast materials used for ovarian tumor imaging 
are extravascular-extracellular agents. Ricke et al. noted that conventional intravenous MR contrast agents can 
improve sensitivity, but sensitivity is location dependent and varied from 38% to 83% in locations such as omen-
tum, lesser sac, bladder, bowel, mesentery and lower pelvis6. Thus, conventional extra-vascular-extracellular 
contrast agents have limited utility for detection. In addition, they enhance tumors for a short duration on the 
Figure 5. Optical imaging and ex vivo organ distribution of DM-Dual-Gd-ICG in HeyA8 and OVCAR-3 
tumor-bearing mice 2 days after injection. Near infrared fluorescence images of DM-Dual-Gd-ICG uptake 
by intraperitoneal HeyA8 tumors (A) and different organs (B). Near infrared fluorescence images of DM-Dual-
Gd-ICG uptake by intraperitoneal OVCAR-3 tumors (C) and different organs (D). Near infrared fluorescence 
images of ICG uptake by intraperitoneal (E) HeyA8 tumors or (F) OVCAR3 tumors and different organs.
www.nature.com/scientificreports/
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order of a few minutes but not days, as we confirmed, limiting their utility for multipurpose (detection, surgical 
planning, and intraoperative imaging) applications.
Due to abnormal angiogenic and lymphatic vessels, most solid tumors exhibit enhanced permeability and 
retention (EPR) effect29, enabling nanoparticle localization and extended residence. We reasoned that the long 
residence time of DM-Dual-Gd-ICG could be advantageous by allowing MR and then later optical imaging. 
Indeed, DM-Dual-Gd-ICG was visible by MR two days after injection and could be imaged by optical imaging 
afterwards. Liposomes with a similar lipid composition as DM-Dual-Gd-ICG have been shown to be retained in 
tumors for more than five days11. Practically, such wide time windows would afford sufficient time for pre-surgical 
MR imaging followed by NIR imaging at surgery.
Liposomes are subject to reticuloendothelial system (RES) uptake in the liver and spleen. In order to limit 
this and extend circulation time, the liposomes were coated with polyethylene glycol (PEG). Physiologically, the 
liposomal nanoparticle is expected to be removed from the body via hepatobilliary excretion into in the duode-
num from where it may reflux into the stomach and will travel through the bowel. Distinguishing signal from 
nanoparticles in the lumen of bowel is aided by peristalsis, which results in movement of nanoparticles in the 
lumen in a living subject. This concept is commonly used clinically to understand if signal is arising from material 
in the bowel.
Gadolinium based contrast agents cause T1-shortening, resulting in positive image contrast. 
DM-Dual-Gd-ICG is based on the dual-Gd platform meaning that Gd is found on both the surface and within 
the liposome. This increases Gd/particle resulting in greater signal/particle than particles with Gd only on the 
surface or only encapsulated, and results in approximately 10,000 times greater relaxivity/particle than traditional 
extravascular-extracellular contrast agents10.
Incorporation of ICG enabled optical imaging, which has numerous advantages such as high sensitivity and 
spatial resolution, real-time high frame rate imaging, relatively low cost, portability, and lack of ionizing radiation 
exposure20. ICG fluoresces in the near infrared wavelengths, where there is negligible autofluorescence as well as 
limited scatter and absorption in the body. This results in low background and greater tissue penetration to enable 
deeper optical imaging. At high doses (approximately 10 fold greater amount than the encapsulated material we 
delivered), intravenously delivered free ICG alone can result in optical signal in ovarian tumors, theoretically 
by behaving as a macromolecule via binding serum proteins like albumin, but signal in tumor is lost with time, 
such as 24 versus 6 hours after injection30. We did not find free ICG to result in increased signal in tumors at 
48 hours at doses equivalent to DM-Dual-Gd-ICG, so free ICG binding serum proteins was not the mechanism 
of increased signal in tumor, rather it was due to ICG bound in DM-Dual-Gd-ICG. Free ICG has a short plasma 
half-life (~2–4 minutes)18,19. Encapsulation increases circulation time and delays maximal hepatic accumulation20. 
Encapsulation can also increase in vivo stability, and signal intensity21. A few mouse studies support the concept 
Figure 6. Semi-quantitative evaluation of near infrared fluorescence by HeyA8 tumors (A, *P < 0.05, n = 6) or 
OVCAR3 tumors (B, *P < 0.05, n = 5) 2 days after mice were injected with DM-Dual-Gd-ICG or vehicle. Semi-
quantitative evaluation of near infrared fluorescence by HeyA8 tumors (C, n = 6) or OVCAR3 tumors (D, n = 6) 
from mice injected with ICG.
www.nature.com/scientificreports/
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of fluorescent imaging of peritoneal ovarian tumor30–35. These do not include an MR component and are generally 
targeted to one biomarker, limiting their utility to subsets of ovarian tumors. Satpathy et al. reported on iron oxide 
nanoparticles bound to a HER-2 antibody labeled with NIR-83036. This is interesting work. Limitations to iron 
oxide nanoparticles are that they result in more difficult to see negative contrast and generally are not currently 
used in the clinic. The targeted particles detected only some of the evaluated ovarian cell lines36. Mechanistically, 
nanoparticles such as DM-Dual-Gd-ICG localize to tumors via enhanced permeability and retention, which is 
not biomarker restricted. Variability in uptake of lipid-based nanoparticles by tumors, even by tumors derived 
from a single cell line, has been noted11. There was expected variability in MR and NIR signal in OVCAR-3 and 
HeyA8 derived tumors, but in all tumors, uptake was found; thus, variability in uptake did not prevent tumor 
detection in two different ovarian tumor models, suggesting that imaging based on DM-Dual-Gd-ICG is robust. 
Production of DM-dual-Gd-ICG was reproducible with five different batches demonstrating similar characteris-
tics. Although this paper evaluated ovarian tumor models, the imaging methods described herein should also be 
applicable to other solid cancers.
For optical imaging, only two fluorophores (ICG and fluorescein) are FDA approved and between these, ICG 
is the only approved NIR fluorophore37. The components of DM-Dual-Gd-ICG have been used clinically, includ-
ing ICG, liposomes, and gadolinium chelates. MR machines are readily available and for the operating room 
environment, NIR cameras have been described22,38,39. Thus, there is potential for clinical translation.
DM-Dual-Gd-ICG was designed to serve as both a positive MR contrast agent and a NIR optical probe. In 
this study, we found that DM-Dual-Gd-ICG detected intraperitoneal implants in two different peritoneal human 
ovarian cancer models by two different modalities after a single injection. Although DM-Dual-Gd-ICG will 
require safety testing, the use of components found in FDA approved drugs to synthesize DM-Dual-Gd-ICG as 
well as the wide time window for imaging of days after administration should facilitates practical translation of 
this method. The current findings suggest clinical potential for using a single injection of a single nanoparticle 
(DM-Dual-Gd-ICG) to localize ovarian tumors by MR for pre-surgical planning and by NIR at the time of sur-
gery to guide resection.
Methods
DM-Dual-Gd-ICG. 1,2-Dipalmitoyl-sn-Glycero-3-Phosphatidylcholine (DPPC), cholesterol (Chol), and 
diethylenetriaminepentaacetic acid-bis (stearylamide) gadolinium salt (Gd-DTPA-BS) were purchased from 
Avanti Polar lipids (Alabaster, AL, USA). N-(carbonyl-methoxy polyethylene glycol 2000)-1,2-Distearoyl-sn-
Glycero-3 phosphatidylethanolamine (mPEG-2000-DSPE) was purchased from Genzyme Pharmaceuticals 
(Cambridge, MA, USA). Indocyanine green (ICG) was obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Whatman Nuclepore polycarbonate track-etch membranes of 100 and 400 nm pore sizes were purchased from 
Fisher Scientific (Waltham, MA, USA). Dual-Gd liposomes consisting of encapsulated and surface Gd with a 
nominal 150 mM lipid content and encapsulating ICG were made as follows.
Lipids consisting of 30:40:5:25 mole percent of DPPC:Chol:DSPE-mPEG-2000-DSPE:Gd-DTPA-BS were dis-
solved in ethanol at 65 °C. A 1.5 mM solution of ICG was made in deionized (DI) water. This was used to make a 
65 μ M solution of ICG in gadobenate dimeglumine (505 mg/ml, Bracco Diagnostics Inc., Princeton, NJ, USA). 
The lipids dissolved in ethanol were then hydrated with this solution to encapsulate the ICG and gadobenate 
dimeglumine using constant stirring for 30 minutes at 65 °C. Ethanol content was 10% by volume of the total 
suspension. The liposomes were then extruded 5 times through 400 nm followed by 6 extrusions through 100 nm 
Nucleopore membranes using a high-pressure extruder (Northern Lipids, Vancouver, BC, Canada). Extrusions 
were done at 65 °C.
The liposomal suspensions were diafiltered using a MicroKros module (Spectrum Laboratories Inc., CA, 
USA) of 500 kDa molecular weight cutoff (MWCO) membrane tubes to remove unencapsulated ICG and Gd 
(gadobenate dimeglumine). 10 mM histidine with 140 mM saline (pH~7.4) was used as the replacement buffer.
Total Gd and P (phospholipid) content of the liposomal formulations was determined by inductively-coupled 
plasma optical emission spectroscopy (ICP-OES, Model Optima 4300D, Perkin Elmer, Norwalk, CT, USA) oper-
ating at a wavelength of 336.223 nm for gadolinium, and 213.617 nm for phosphorus. The phosphorus levels 
were used to estimate the total lipid concentration, since the phospholipids are the only phosphorus-containing 
component of the formulation. Liposome particle size was determined using a BI-90 Brookhaven Instruments 
Dynamic Light Scattering instrument (Brookhaven Instruments Corp., Holtsville, NY, USA) using a 532 nm laser, 
90° scattering angle and Hamamatsu photomultiplier. The correlation function was fitted using a cumulants anal-
yses. The measurement was repeated on separate samples (N = 3) of each batch. The Z-average (mean) diameter 
and polydispersity were recorded for each measurement. The correlation function was also inverted using the 
CONTIN algorithm, and the intensity-weighted distribution of particle sizes that resulted was converted to a 
volume-weighted distribution using the Mie coefficients at the mid-point of each size interval in the histogram. 
Cumulative size distributions were calculated using the volume-weighted distributions, and the cumulative frac-
tions below 100 nm, below 150 nm and below 200 nm were reported.
In order to study leakage of encapsulated Gd chelate and ICG from the liposomes (3 different batches used) 
in plasma at 37 °C over time, 100 μ l of liposomes were incubated with 500 μ l of bovine plasma at 37 °C for 2, 6, 21, 
29, and 48 hours. After the incubation, the samples were diluted 30 times with histidine-saline and the liposomes 
were ultracentrifuged at 103, 250 × g for 1.25 hours at 18 °C using a Beckman L7-65 ultracentrifuge with a SW55 
Ti rotor. The supernatant was collected and analyzed by ICP for Gd content, and by a lab-built NIR camera system 
for ICG content. No incubation was used as background and was subtracted from above. ICG was measured using 
a lab-built NIR camera system, consisting of led lights with a cutoff filter of 780 nm for the excitation of ICG. 
Images were acquired by a camera fitted with a 810–830 nm bandwidth filter (for ICG emission). ICG standards 
between 0.002–0.2 μ M were made and images were acquired. A standard curve was generated by drawing a ROI 
www.nature.com/scientificreports/
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(same dimension for all standards) in the cuvettes holding the standards and measuring the intensities. The same 
ROI was used to measure the samples.
T1 relaxation rate (R1) measurements of two different batches of DM-Dual-GD-ICG used for animal 
experiments were performed. Dilutions were imaged in a 4.7T MR (47/40 USR, Bruker Biospin, Billerica, 
MA). Quantitative T1 relaxation measurements were performed using a fast spin-echo saturation-recovery 
sequence (TR = 110–10000 ms [110 ms, 200 ms, 400 ms, 600 ms, 1000 ms, 2000 ms, 4000 ms, 6000 ms, 10000 ms]; 
TE = 50 ms; echo train = 8; field of view (FOV) = 4 cm × 3 cm; Image matrix = 128 × 128; number of sig-
nal averages = 1). T1-value was measured using a region of interest (ROI) encompassing each tube containing 
DM-Dual-Gd-ICG. Paravision version 4 was used to calculate the T1 relaxation values by exponentially fitting 
of signal as a function of TR. The relaxation rates (R1) of the diluted samples were obtained using the inverse of 
these values.
For assessing NIRF, two different batches of DM-Dual-Gd-ICG were individually diluted in saline. Samples 
were analyzed using a Xenogen IVIS 200 system (Perkin Elmer Inc., Waltham MA). Total radiant efficiency (p/s)/
(μ W/cm2) was determined using ICG (λ excitation = 705–780 nm and λ emission = 810- 885 nm) filters and drawing a 
region of interest (ROI) encompassing each well.
Animals. Twelve female nude mice (6–8 weeks old) were acquired from the Experimental Radiation 
Oncology Department at UT- MD Anderson Cancer Center (Houston, TX) and housed in specific pathogen-free 
conditions. They were cared for under the guidelines set forth by the American Association for Accreditation 
of Laboratory Animal Care and all studies were approved and supervised by the MD Anderson Cancer Center 
Institutional Animal Care and Use Committee.
Tumors were established by intraperitoneal injection of 1 × 107 HeyA8 or OVCAR-3 cells using a syringe with 
a 28 gauge needle. At weekly intervals after injection, the mice were monitored for tumor growth. After 3 week, 
mice (n = 6 per group) were randomly assigned to control group or experimental group. Then, the mice were 
injected intravenously with 200 μ l of DM-Dual-Gd-ICG liposomes or vehicle and imaged after two days. Vehicle 
was chosen since clinically, the most appropriate control is enhancement pre vs post contrast agent imaging; and, 
in this manuscript we wanted to demonstrate the dual mode (MR and optical) nature of the nanoparticle.
As controls, mice (n = 6) bearing intraperitoneal HeyA8 or OVCAR3 tumors were injected intravenously with 
free (non-encapsulated) ICG or gadobenate dimeglumine, for robustness, delivered at the full dose delivered with 
DM-Dual-Gd-ICG. For MR, imaging was performed before, immediately after, and two days after intravenous 
injection. NIR imaging was performed two days after intravenous injection.
Magnetic Resonance Imaging. All MR studies were performed using a 4.7 T scanner (Bruker Biospec, 
47/40 USR, Bruker Biospin, Billerica, MA) with a 60 mm gradient insert and a volume resonator with a 35 mm 
inner diameter. Animals were anesthetized and placed head first and prone on a positioning sled. Orthogonal 
3-plane scout scans were initially acquired to confirm animal positioning. Animal placement and tumor location 
were confirmed using images from a respiratory gated axial T2-weighted fast spin echo sequence, which essen-
tially served as a localizer sequence (repetition time = 3813 ms, effective echo time (TE) = 57 ms, echo train = 12; 
field of view (FOV) = 4 × 3 × 4 cm, slice thickness = 1 mm, image matrix = 256 × 192, number of signal aver-
ages = 3, spatial resolution, 156 Am, flip angle = 180). For T1-weighted imaging, axial 2D fast spoiled gradient 
echo (2D-FSPGR) sequence (TR = 120.54 ms; TE = 1.50 ms; echo train = 1; field of view (FOV) = 3 × 3 × 4 cm; 
slice thickness = 1 mm; image matrix = 128 × 128; number of signal averages = 20, flip angle = 90) and coronal 
3D fast spoiled gradient echo (3D-FSPGR) sequence (TR = 6.9 ms; TE = 1.56 ms; echo train = 1; field of view 
(FOV) = 3 × 5 cm; slice thickness = 0.625 mm; image matrix = 192 × 192; number of signal averages = 6, flip 
angle = 20) were acquired. The axial 2D fast spoiled gradient echo sequence was used to measure the signal inten-
sity of the tumor tissue. Signal-to-noise (SNR) and contrast-to-noise (CNR) were calculated by manually drawn 
regions of interest (ROI) around the periphery of each slice containing tumor, muscle and background (air) using 
Bruker ParaVision 5.1 software. The SNR was measured as SIT/SD where, SIT is the mean signal intensity of the 
tumor and SD is the standard deviation of the signal intensity of the background. The CNR was calculated as 
(SIT − SIm)/SD, where SIm is the mean signal intensity of the muscle. SNR and CNR were measured for each tumor 
and the average values were presented for each group. 
Near Infrared-Fluorescent Imaging. After MR imaging, the animals were sacrificed and immediately, 
NIR imaging of the open abdomen was performed. Tumors and organs (heart, lungs, liver, spleen, kidney, stom-
ach, and intestine) were then dissected and excised, and fluorescence imaging of excised tumor and organs was 
performed. For NIR imaging, a Xenogen IVIS 200 system (Perkin Elmer Inc., Waltham, MA, USA) was used. 
ICG fluorophore excitation (λ excitation = 705–780 nm) and emission (λ emission = 810–885 nm) filter sets were used. 
Using Living Image 2.5 software, regions of interest (ROI) were drawn for each organ/tumor and total radiant 
efficiencies (p/s)/(μ W/cm2) were measured.
Statistical Analysis. For comparing groups, Student’s two-tailed t-tests were performed using spreadsheet 
software (Microsoft Office Excel, 2010; Seatle, WA). A p value of ≤ 0.05 was considered statistically significant.
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